Patients infected by the human immunodeficiency virus are predisposed to many infectious and noninfectious complications and often receive a variety of drugs. Furthermore, they seem to have a particular susceptibility to idiosyncratic adverse drug reactions. It is therefore surprising that only a few cases of the neuroleptic malignant syndrome have been described in patients with the acquired immunodeficiency syndrome. A high index of suspicion is required to diagnose the neuroleptic malignant syndrome in these patients, as its usual manifestations, including fever and altered consciousness, are frequently attributed to an underlying infection.
Epidemiology
Agitation and other psychotic symptoms are common in HIV-infected patients and they are frequently treated with neuroleptics. In fact, apathy, social withdrawal and personality changes have been reported to occur even before the development of the typical manifestations of HIV infection. 9 In addition, neuroleptic-related drugs are commonly used to control other symptoms, such as nausea and vomiting.
The first case describing the association of NMS with AIDS was reported in 1986 by Bernstein and Scherokman, in a patient with disseminated histoplasmosis. Up to date, only eight cases of this association have been reported (see table) . However, the actual incidence of NMS in the setting of AIDS is unknown. It is likely that many cases still go unrecognised because of the limited knowledge of this syndrome by clinicians. In a recent study, the majority of healthcare professionals tested did not know enough about NMS to aid early detection and to prevent its high mortality.'0 NMS can occur in all age groups, but is more often found in young and middle-aged adults." Among AIDS patients, NMS also predominantly affects young men (table). The average age was 34.1 years (range 21 to 49). The drugs most frequently implicated in AIDS-related NMS have been haloperidol, trimethobenzamide and prochlorperazine.
Pathogenesis and risk factors
NMS is considered an idiosyncratic reaction to antipsychotic and related drugs. The prevailing theory relates NMS to a profound decrease of dopaminergic function in the central nervous system. The loss of dopaminergic activity in the nigrostriatal system would cause rigidity and tremor. The sustained muscle activity would result in increased production of heat, which, together with the alteration of hypothalamic and other autonomic centres, may cause fever and rhabdomyolysis."1"'
The incidence of extrapyramidal side-effects due to neuroleptics and related drugs, including metoclopramide, is increased in AIDS patients.'3"14 The cause of this higher frequency of adverse effects remains speculative, but is probably related to the presence of predisposing structural brain abnormalities, due to opportunistic infections or to HIV infection itself. In this sense, the report of Reyes et al, showing that nigral degeneration is common in AIDS patients is interesting,'5 as this would certainly predispose to extrapyramidal effects.
Case report
A 32-year-old HIV seropositive white man with a previous diagnosis ofAIDS (stage C3 according to CDC criteria), presented with pneumonia. He was an intravenous drug abuser with eight months of abstinence, and there was no history of dementia or psychiatric disorders.
The patient was febrile and inspiratory crackles were heard over the lowest third of right lung. The remainder of the examination was normal. Chest X-ray showed an alveolar infiltrate in the right lower lobe. Intravenous erythromycin and cefotaxime were given. Blood cultures yielded Streptococcus pneumoniae and erythromycin was withdraw. By the fifth day he became afebrile.
On hospital day 11, the patient developed agitation and paranoid ideations. He was started on haloperidol (6 mg/day per os), and oral biperiden. Three days later, the patient became febrile (39.50C), with tachycardia, tachypnoea, profuse diaphoresis, cogwheel rigidity of all extremities, akinesia and fluctuating consciousness with mutism. Leukocytosis with a left shift was present, and creatine kinase level was 2365 U/1. Exhaustive microbiological studies were negative. Chest X-ray showed no infiltrates. A cranial CT scan was normal, and CSF examination and cultures failed to reveal any evidence of infection. Haloperidol was discontinued. Within 48 h his temperature, creatine kinase and neurological status were normal. However, psychotic symptoms recurred and oral loxapine (100 mg/ day) was given. One day later fever (39°C), stupor, and extrapyramidal signs reappeared. As before, no evidence for infection was found. By the second day after loxapine withdrawal his body temperature and neurologic status were again normal. 
Clinical features SYMPTOMS AND SIGNS
The characteristic tetrad of NMS includes hyperthermia, extrapyramidal rigidity of skeletal muscles, fluctuating consciousness, and instability of the autonomic nervous system. 11,12,18 Symptoms and signs of NMS in AIDS patients are summarised in the table. The clinical features of patients with AIDS do not seem to differ from those observed in other patients with NMS. Hyperthermia was constant in all patients; in about half body temperature was higher than 40'C. Extrapyramidal-type hypertonia, often along with bradykinesia or akinesia, was also present in the vast majority of patients. Rigidity of the thoraco-abdominal muscles may result in hypoventilation and respiratory failure (cases 5 and 9). Tremor was present in two patients.
The development of the complete NMS may be preceded by insidious changes in mental status or autonomic functions. All AIDS-patients with NMS displayed alteration of consciousness, psychomotor excitement or aggressive behaviour before the onset of the full syndrome. In AIDS-patients the most common signs of autonomic dysfunction were tachycardia, tachypnoea and diaphoresis. Mild dysphagia was present in one case.
Most cases developed in the first week after initiating the offending drug, but in two patients NMS was diagnosed later. Symptoms usually developed over a period of 24 to 72 hours, and the mean recovery time was five to 10 days.
LABORATORY FINDINGS
Leucocytosis with or without a left shift is very common.""2'18 However, the number of leukocytes was not always reported in the published cases of NMS and AIDS. Therefore, it is unclear how frequent leucocytosis is in this population who often have previous leucopenia. Most patients with NMS also show an elevated serum creatine kinase level, probably due to myonecrosis during sustained muscle contraction. It may evolve into frank rhabdomyolysis and renal failure, the most common serious complication of NMS. Most patients with AIDS and NMS showed elevated serum creatine kinase levels, but acute renal failure only occurred in one case.' However, it must be stressed that the diagnosis should not over-rely on increased creatine kinase levels, as this is a common and nonspecific finding in patients taking neuroleptics who become infected. 9 Electroencephalograms were normal or showed nonspecific signs of encephalopathy. Cerebrospinal fluid (CSF) was normal or presented a nonspecific slight increase in proteins. Cranial computed tomography (CT) showed no abnormalities. Albeit non-diagnostic, those tests served to rule out opportunistic infections before making the diagnosis of NMS in the setting of AIDS.
Diagnosis
There is no universal agreement about the diagnostic criteria for NMS, although several sets of criteria have been proposed. Among the more widely Given the lack of consensus about diagnostic criteria, it is not surprising that the reported frequency of NMS had varied from 0.07 to 12.2%."""" l One However, although an infection must certainly be excluded in any patient presenting with fever, it should be realised that infection and NMS are not mutually exclusive, specially in the setting of AIDS. Thus, in an infected patient taking neuroleptics or other drugs capable of causing NMS, the clinician should consider critically whether the infectious process itself explains all the clinical manifestations. In this scenario, the presence of muscle rigidity would be particularly suspicious of a drug reaction and prompt the discontinuation of the potentially offending drug.
Prognosis
The mortality of NMS ranges from 10 to 30% in most studies."""""l5 6 In AIDS patients mortality was 33%. Causes of death were respiratory insufficiency (case 5), acute renal failure and rhabdomyolysis (case 6), and sepsis (case 7 Figure Suggested approach to AIDS patients with drug-induced extrapyramidal manifestations of NMS. Yet the distinction has important therapeutic importance. In the former case, anticholinergics could ameliorate the symptoms, whereas in NMS they may worsen hyperpyrexia. Thus, in doubtful cases, neuroleptics must be stopped ( figure) . Although still unproved, it is expected that stopping neuroleptics at early stages of NMS may prevent the development of the fullblown syndrome or ameliorate its severity. About one third of patients who recover from NMS experience a recurrence when treated again with neuroleptics. If these drugs need to be given, delaying therapy for two or more weeks after complete recovery, use of low-potency drugs, and correction of other risk factors may help to decrease recurrence rate.1"112
